We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NLRP3

News List

Zydus announces Phase I trials of ZYIL1, oral small molecule NLRP3 inflammasome inhibitor expresspharma
December 08, 2020
NLRP3 inflammasomes lead to the onset and development of diseases like ARDS, auto-immune diseases, inflammatory diseases, CVDs, metabolic disorders, gastrointestinal diseases, renal diseases and CNS diseases.
Zydus Cadila files IND application for ZYIL1, NLRP3 inflammasome inhibitor expresspharma
November 05, 2020
Zydus announced that it has filed the IND application of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. Following up on its initiatives to fight COVID 19 with diagnostics, vaccines and therapeutics, the company is now focussing on ...